Supplementary Figure legends
(A) FLIM-FRET measurements of mGFP-H-rasG12V and mRFP-Gal-1 complexation in BHK21 cells with or without 5 µM compactin treatment. While compactin treatment reduced the FRET significantly, FRET was still in agreement with a complexation between H-rasG12V and Gal-1 in the cellular cytoplasm. Plotted values represent the mean ± SEM and numbers inside the bars correspond to the total number of cells imaged in each case. Statistical differences between compactin treated and untreated cells were calculated as described in Methods from three independent biological repeats (***, p < 0.001).
(B) Interaction between non-farnesylatable mGFP-H-rasG12V-C186S and mRFPtagged Gal-1, as well as mGFP-H-rasG12V and putative farnesyl-pocket mutant Gal-1-K29T studied using FLIM-FRET in HEK293-EBNA cells transiently expressing indicated constructs. As compared to the positive control H-rasG12V and C-Raf-RBD, the binding between H-rasG12V-C186S and C-Raf-RBD was decreased due to the loss of H-ras plasma membrane anchorage, where H-rasG12V exhibits a higher recruitment efficiency 1 . However, significant FRET between H-rasG12V-C186S and Gal-1 was still retained. In addition, the mutation K29T in Gal-1 could not disrupt the complexation between H-rasG12V and Gal-1, as the FRET compared to the (FRET-) control sample was statistically significant (not indicated). Samples coexpressing mGFP and mRFP served as a FRET control.
(C) Schematic representation of ACP-tag protein expression and fluorescence labelling for in vitro experiments. Recombinantly expressed and purified proteins were used for studies in solution. The protein expression plasmid pQE-A1 was constructed on the basis of commercial pQE-30 Xa vector (Qiagen). The pQE-A1-plasmid has BglII and KpnI restriction sites for sub-cloning of different genes of interest. The final fusion protein consists of four functional elements: 1) the Nterminus contains 6-His affinity tag for purification on a nickel chelate column; 2) the PreScission protease recognition site for a site-specific protease cleavage (indicated by the scissors); 3) the A1-tag is an alternative acyl carrier protein (ACP)-tag (NEB) with a short amino acid sequence (12 aa) used for selective fluorescent labelling; 4) the final element is the sequence of the protein of interest. ACP labelling reaction:
ACP synthase (4´-phosphopantetheinyl transferase) catalyzes the covalent transfer of substituents from derivatized coenzyme A (CoA) to A1-tagged fusion proteins in solution. The A1-tag is a small tag (8 kDa) based on the acyl carrier protein (ACP) that allows the specific, covalent attachment of virtually any molecule to a protein of interest. Substrates for labelling are derivatives of coenzyme A (CoA). In the labelling reaction, ACP Synthase covalently attaches the substituted phosphopantetheine group of CoA to a serine residue on the A1-tag.
(D) Hemagglutination assay with mouse red blood cells to test and compare purified A1-Gal-1 and His-A1-Gal-1 carbohydrate-binding activity. The graph depicts mean maximum OD values versus 1:2 serial dilutions of proteins combined with 30 µl red blood cell suspension. The transmission characteristics of a suspension of red blood cells are determined by the combined effect of the absorption by intracellular hemoglobin and the scattering from the cells. Both these parameters are affected by the shape and volume of the cells. A decrease in OD from left to right correlates with spread out red blood cells (positive outcome). Concanavalin A is a positive control.
The high concentration ranges where the two curves meet indicates overlapping hemagglutination properties of Gal-1 variants with those of concanavalin A samples 2 .
On the other hand, at low concentration ranges where there is no galectin-induced hemagglutination, the two curves stay separated unlike the positive outcome from concanavalin A samples. Data points are means ± SEM from two individual biological repeats.
(E) Representative western blots from HEK293-EBNA cellular lysates expressing indicated constructs immobilized on lactose agarose beads. Cells transfected with the carbohydrate-binding deficient mutant (mRFP-Gal-1-N47D,W69L) and untransfected cells serve as controls. The load, flow-through (unbound fraction), and elution (retained fraction) were analysed using a Gal-1 antibody. Right panel shows repeated experiment with higher amount of load. Arrow points to the position of bands corresponding to mRFP-labelled Gal-1 proteins (between 37 kDa -50 kDa). Statistical significance between treated samples and marked control (dark grey) was determined as described in Methods (ns, nonsignificant; ***, p < 0.001).
(C) Multiple sequence alignment of human A-, B-and C-Raf-and PI3Kα-RBDs.
Top panel: Shown here are the Ras-binding region, which harbour major binding residues with Ras, and candidate C-Raf-RBD/ Gal-1 interface residues at distance less than 5Å (red arrowheads) from Gal-1. Key residues that abolished RBD/ Gal-1 complex formation in experiments after they were mutated to alanine are marked with asterisks. Nuclear import (NLS) and export (NES) sequence stretches with high 
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